## 13th International Conference on Allergy, Immunology & Rheumatology

September 30, 2021

## Comparison of Dabigatran with Warfarin in Treatment of Acute Deep Vein Thrombosis in View of Efficacy and Safety

## Jalpa Suthar

Ramanbhai Patel College of Pharmacy, India

**Background**: The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism. Dabigatran was proven to have similar effect on the prevention of recurrence of venous thromboembolism and a lower risk of bleeding compared to vitamin K antagonists. This study aimed to compare the safety and efficacy of Dabigatran with Warfarin in patients with DVT.

Materials and Methods: A retrospective study in patients with DVT who received dabigatran 110 mg twice and warfarin 50 mg once in a day for treatment of DVT. Demographic details, drug treatment, medical history, presenting complains and diagnosis was recorded in CRF. Descriptive statistical analysis was done using MS Excel.

**Results**: In total, 60 patients with DVT were divided into 2 treatment groups (30 to dabigatran and 30 to warfarin). Out of total patients, 15 (25%) patients from 31-40 age group and 37 (62%) were women seen higher prevalence. The duration of treatment was 6 months. Majority of them 32 (53.4%) had Poplitial femoral DVT. Dabigatran treatment group 26 (86.6%) showed better recanalization at the end of the 6-month treatment duration while in Warfarin there are 15 (50%) patients. All the parameters had significant differences except for patients who had pulmonary embolism even on medications. There was no patient in dabigatran group who had bleeding while 3 (10%) patients in warfarin group had bleeding.

**Conclusion**: For the treatment of acute DVT, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfarin, and does not require laboratory monitoring. The findings of the study will give new insights into the selection of treatment regimens in patients with DVT.

## **Biography**

Jalpa Suthar is presently working as an associate professor at, Department of Pharmacology & Clinical Pharmacy, Ramanbhai Patel College of Pharmacy, CHARUSAT, Changa. She has a total 14 years of teaching experience including 10 Years of research experience in Pharmacy field. She has to her credit 23 national and international research publications in reputed journals. She has guided 17 M.Pharm students & 2 students perusing PhD under her guidance. She has awarded by "Late Smt VG Yeole memorial Award" in the 23rd National Annual APTI convention APTICON-2018 for the best paper publication in Indian Journal of Pharmacy Practice. She has presented 15 posters and oral papers at various national and international colleges and presented paper at 7th International Conference on Clinical Trials, September 24-26, 2018 at Chicago, USA. She has received Travel Grant from Indian Council of Medical Research (ICMR) of Rs 95,922/- towards the travel expenses and visa fees to attend 5th International Conference on Clinical Pharmacy and Health Care, September 17-18, San Antonio, USA. Also received Travel Grant from Council of Scientific and Indian Research (CSIR) of RS. 30,000/-.

jalpasuthar.ph@charusat.ac.in